BPG is committed to discovery and dissemination of knowledge
Articles in Press
1/16/2024 6:09:27 AM | Browse: 36 | Download: 0
Publication Name World Journal of Gastrointestinal Surgery
Manuscript ID 89368
Country China
Category Pharmacology & Pharmacy
Manuscript Type Meta-Analysis
Article Title Is tumor necrosis factor-α monoclonal therapy with proactive therapeutic drug monitoring optimized for inflammatory bowel disease? Network meta-analysis
Manuscript Source Unsolicited Manuscript
All Author List Fang-Yuan Zheng, Kai-Si Yang, Wen-Cheng Min, Xin-Zhu Li, Yu Xing, Shuai Wang, Ying-Shi Zhang and Qing-Chun Zhao
Funding Agency and Grant Number
Funding Agency Grant Number
National College Students Innovation and Entrepreneurship Training Program of Shenyang Pharmaceutical University  No. 202210163003
Corresponding Author Ying-Shi Zhang, N/A, Lecturer, Teacher, Department of Clinical Pharmacy, Shenyang Pharmaceutical University, No. 103 Wenhua Road, Shenhe District, Shenyang 110016, Liaoning Province, China. zhangyingshi526@163.com
Key Words Inflammatory bowel disease; Therapeutic drug monitoring; Adalimumab; Infliximab; Network meta-analysis
Core Tip The efficacy and safety of anti-tumor necrosis factor-α monoclonal antibody therapy [adalimumab (ADA) and infliximab] with therapeutic drug monitoring (TDM), which has been proposed for inflammatory bowel disease (IBD) patients, are still controversial. In this study, we found that proactive TDM was more suitable for IBD patients treated with ADA and had obvious advantages over reactive TDM.
Citation Zheng FY, Yang KS, Min WC, Li XZ, Xing Y, Wang S, Zhang YS, Zhao QC. Is tumor necrosis factor-α monoclonal therapy with proactive therapeutic drug monitoring optimized for inflammatory bowel disease? network meta-analysis. World J Gastrointest Surg 2024; 16(2): 571-584
Received
2023-10-29 14:04
Peer-Review Started
2023-10-29 14:06
To Make the First Decision
Return for Revision
2023-12-06 06:23
Revised
2023-12-14 13:17
Second Decision
2024-01-16 02:46
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief
2024-01-16 06:09
Articles in Press
2024-01-16 06:09
Publication Fee Transferred
Edit the Manuscript by Language Editor
2024-01-14 14:28
Typeset the Manuscript
2024-02-07 07:57
ISSN 1948-9366 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com